Segal Lawrence, Morelle Danielle, Blee Mark, Moore Emma, Damsten Micaela, Liu Kai Chiu, Destexhe Eric, Garçon Nathalie
GSK Vaccines, Rixensart, Belgium.
GSK Vaccines, Rixensart, Belgium.
Regul Toxicol Pharmacol. 2015 Mar;71(2):269-78. doi: 10.1016/j.yrtph.2014.12.017. Epub 2014 Dec 27.
RTS,S malaria antigen is weakly immunogenic as such and needs to be formulated with an adjuvant to improve the magnitude and duration of the immune responses to RTS,S. Two Adjuvant Systems, AS01 and AS02 were evaluated during the development of the RTS,S vaccine. The evaluation included non-clinical studies in rabbits to evaluate the local intramuscular tolerance following administration on a single occasion, and the local and systemic effects following repeated administrations of RTS,S/AS01 or RTS,S/AS02 formulations. In the first study, rabbits were injected on one occasion with RTS,S/AS01, RTS,S/AS02 or controls, and the local intramuscular tolerance was evaluated up to 3 days after injection. In the second study, the different formulations were injected on Days 0, 14, 28 and 42. General health status, haematology and blood chemistry parameters were monitored on a regular basis. Macroscopic and microscopic evaluations were made after termination of the study. No sign of toxicity was detected following single or repeated administrations of the adjuvanted RTS,S formulations. Changes in haematology or clinical chemistry parameters were indicative of a developing immune response in the groups receiving either RTS,S formulation. All examined parameters returned to normal within 28 days after the last injection. The absence of toxicological effects following the injection of RTS,S/AS01 or RTS,S/AS02 in rabbits was supportive of further clinical evaluation of these two formulations.
RTS,S疟疾抗原本身免疫原性较弱,需要与佐剂配合使用,以提高对RTS,S免疫反应的强度和持续时间。在RTS,S疫苗的研发过程中,对两种佐剂系统AS01和AS02进行了评估。评估包括在兔子身上进行的非临床研究,以评估单次给药后的局部肌肉耐受性,以及重复给药RTS,S/AS01或RTS,S/AS02制剂后的局部和全身影响。在第一项研究中,给兔子单次注射RTS,S/AS01、RTS,S/AS02或对照品,并在注射后3天内评估局部肌肉耐受性。在第二项研究中,在第0、14、28和42天注射不同的制剂。定期监测一般健康状况、血液学和血液化学参数。研究结束后进行宏观和微观评估。单次或重复给予佐剂RTS,S制剂后未检测到毒性迹象。血液学或临床化学参数的变化表明接受任何一种RTS,S制剂的组中正在产生免疫反应。最后一次注射后28天内,所有检测参数均恢复正常。在兔子中注射RTS,S/AS01或RTS,S/AS02后未出现毒理学效应,这支持对这两种制剂进行进一步的临床评估。